Our results reveal reverse correlations of metformin treatment with the incidence of distant metastasis and poorly differentiated adenocarcinoma, the positive rate of CD133 and the expression of β-catenin protein in CRC patients with type 2 DM. Here, PROM1 is linked to adenocarcinoma.